



\$100 Million
Initial Public Offering



Joint Bookrunner
November 2023

Leerink Partners Serves as Joint Bookrunner for Lexeo Therapeutics' (Nasdaq: LXEO) \$100 Million Initial Public Offering

Key Transaction Highlights

- Priced on November 2nd, 2023, at \$11.00 per share
- Based deal consisted of 9,090,910 shares of common stock.
- Lexeo intends to use the net proceeds from this offering, together with its existing cash, to advance the clinical development of LX2006, LX2020, and LX1001, to fund the continued development of its other programs and cardiac discovery efforts, and for working capital and other general corporate purposes.
- This transaction represents Leerink Partners' 4th bookrun IPO and 47th equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111